Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A study involving researchers at the Wellcome Trust Centre for Human Genetics has uncovered why some tumours become resistant to an important class of anti-cancer drugs. Women with breast cancer caused by BRCA1 gene mutations can be treated with PARP inhibitors. but some tumours appear to become resistant to this treatment. Dr Ross Chapman collaborated with a research team at the Netherlands Cancer Institute on a recent Nature paper which uncovered the crucial role a protein called Rev7 played in resistance to PARP inhibitors.